Krzysztof Batko, Anna Sączek, Małgorzata Banaszkiewicz, Jolanta Małyszko, Ewa Koc-Żórawska, Marcin Żórawski, Karolina Niezabitowska, Katarzyna Siek, Alina Bętkowska-Prokop, Andrzej Kraśniak, Marcin Krzanowski, Katarzyna Krzanowska
{"title":"长期肾移植受者肾功能的风险预测。","authors":"Krzysztof Batko, Anna Sączek, Małgorzata Banaszkiewicz, Jolanta Małyszko, Ewa Koc-Żórawska, Marcin Żórawski, Karolina Niezabitowska, Katarzyna Siek, Alina Bętkowska-Prokop, Andrzej Kraśniak, Marcin Krzanowski, Katarzyna Krzanowska","doi":"10.3389/fmed.2025.1469363","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Limited tools exist for predicting kidney function in long-term kidney transplant recipients (KTRs). Elabela (ELA), apelin (APLN), and the APJ receptor constitute an axis that regulates vascular and cardiac physiology in opposition to the renin-angiotensin-aldosterone system.</p><p><strong>Methods: </strong>Longitudinal, observational cohort of 102 KTRs who maintained graft function for at least 24 months, with no acute rejection history or active infection upon presentation. Serum APLN, ELA, fibroblast growth factor 23 (FGF-23) and α Klotho were tested using enzyme-linked immunoassay and compared with a control group of 32 healthy controls (HCs).</p><p><strong>Results: </strong>When comparing with HCs, higher serum FGF-23, ELA and APLN, but lower ɑ Klotho concentrations were observed in long-term KTRs. Most KTRs had stable trajectories of renal function. Mean estimated glomerular filtration (eGFR) over 2-year follow-up was associated with significantly lower odds of graft loss (OR 0.04, 95% CI 0.01-0.15; <i>p</i> < 0.001). Baseline renal function was significantly correlated with mineral-bone markers (log[FGF-23]: <i>r</i> = -0.24, <i>p</i> = 0.02; log[α-Klotho]: <i>r</i> = 0.34, <i>p</i> < 0.001) but showed no significant association with aplnergic peptides (APLN: <i>r</i> = -0.07, <i>p</i> = 0.51; ELA: <i>r</i> = 0.17, <i>p</i> = 0.10). Univariable random forest regression indicated that baseline eGFR alone explained 87% of the variance in future 2-year eGFR, suggesting its overarching importance in late-term predictions. Incorporating both simple clinical characteristics and candidate serum biomarkers into a model predicting last available eGFR allowed for moderate predictive performance. In univariable Cox Proportion Hazard models, lower log(α-Klotho) (HR 0.26, 95% CI 0.12-0.58; <i>p</i> = 0.001) and higher log(FGF-23) (HR 2.14, 95% CI 1.49-3.09; <i>p</i> < 0.001) were significant predictors of death-censored allograft loss.</p><p><strong>Conclusion: </strong>Both aplnergic and mineral-bone peptides appear as relevant candidate markers for future studies investigating their predictive performance regarding renal allograft outcomes.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1469363"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965586/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk prediction of kidney function in long-term kidney transplant recipients.\",\"authors\":\"Krzysztof Batko, Anna Sączek, Małgorzata Banaszkiewicz, Jolanta Małyszko, Ewa Koc-Żórawska, Marcin Żórawski, Karolina Niezabitowska, Katarzyna Siek, Alina Bętkowska-Prokop, Andrzej Kraśniak, Marcin Krzanowski, Katarzyna Krzanowska\",\"doi\":\"10.3389/fmed.2025.1469363\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Limited tools exist for predicting kidney function in long-term kidney transplant recipients (KTRs). Elabela (ELA), apelin (APLN), and the APJ receptor constitute an axis that regulates vascular and cardiac physiology in opposition to the renin-angiotensin-aldosterone system.</p><p><strong>Methods: </strong>Longitudinal, observational cohort of 102 KTRs who maintained graft function for at least 24 months, with no acute rejection history or active infection upon presentation. Serum APLN, ELA, fibroblast growth factor 23 (FGF-23) and α Klotho were tested using enzyme-linked immunoassay and compared with a control group of 32 healthy controls (HCs).</p><p><strong>Results: </strong>When comparing with HCs, higher serum FGF-23, ELA and APLN, but lower ɑ Klotho concentrations were observed in long-term KTRs. Most KTRs had stable trajectories of renal function. Mean estimated glomerular filtration (eGFR) over 2-year follow-up was associated with significantly lower odds of graft loss (OR 0.04, 95% CI 0.01-0.15; <i>p</i> < 0.001). Baseline renal function was significantly correlated with mineral-bone markers (log[FGF-23]: <i>r</i> = -0.24, <i>p</i> = 0.02; log[α-Klotho]: <i>r</i> = 0.34, <i>p</i> < 0.001) but showed no significant association with aplnergic peptides (APLN: <i>r</i> = -0.07, <i>p</i> = 0.51; ELA: <i>r</i> = 0.17, <i>p</i> = 0.10). Univariable random forest regression indicated that baseline eGFR alone explained 87% of the variance in future 2-year eGFR, suggesting its overarching importance in late-term predictions. Incorporating both simple clinical characteristics and candidate serum biomarkers into a model predicting last available eGFR allowed for moderate predictive performance. In univariable Cox Proportion Hazard models, lower log(α-Klotho) (HR 0.26, 95% CI 0.12-0.58; <i>p</i> = 0.001) and higher log(FGF-23) (HR 2.14, 95% CI 1.49-3.09; <i>p</i> < 0.001) were significant predictors of death-censored allograft loss.</p><p><strong>Conclusion: </strong>Both aplnergic and mineral-bone peptides appear as relevant candidate markers for future studies investigating their predictive performance regarding renal allograft outcomes.</p>\",\"PeriodicalId\":12488,\"journal\":{\"name\":\"Frontiers in Medicine\",\"volume\":\"12 \",\"pages\":\"1469363\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965586/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fmed.2025.1469363\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1469363","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Risk prediction of kidney function in long-term kidney transplant recipients.
Background: Limited tools exist for predicting kidney function in long-term kidney transplant recipients (KTRs). Elabela (ELA), apelin (APLN), and the APJ receptor constitute an axis that regulates vascular and cardiac physiology in opposition to the renin-angiotensin-aldosterone system.
Methods: Longitudinal, observational cohort of 102 KTRs who maintained graft function for at least 24 months, with no acute rejection history or active infection upon presentation. Serum APLN, ELA, fibroblast growth factor 23 (FGF-23) and α Klotho were tested using enzyme-linked immunoassay and compared with a control group of 32 healthy controls (HCs).
Results: When comparing with HCs, higher serum FGF-23, ELA and APLN, but lower ɑ Klotho concentrations were observed in long-term KTRs. Most KTRs had stable trajectories of renal function. Mean estimated glomerular filtration (eGFR) over 2-year follow-up was associated with significantly lower odds of graft loss (OR 0.04, 95% CI 0.01-0.15; p < 0.001). Baseline renal function was significantly correlated with mineral-bone markers (log[FGF-23]: r = -0.24, p = 0.02; log[α-Klotho]: r = 0.34, p < 0.001) but showed no significant association with aplnergic peptides (APLN: r = -0.07, p = 0.51; ELA: r = 0.17, p = 0.10). Univariable random forest regression indicated that baseline eGFR alone explained 87% of the variance in future 2-year eGFR, suggesting its overarching importance in late-term predictions. Incorporating both simple clinical characteristics and candidate serum biomarkers into a model predicting last available eGFR allowed for moderate predictive performance. In univariable Cox Proportion Hazard models, lower log(α-Klotho) (HR 0.26, 95% CI 0.12-0.58; p = 0.001) and higher log(FGF-23) (HR 2.14, 95% CI 1.49-3.09; p < 0.001) were significant predictors of death-censored allograft loss.
Conclusion: Both aplnergic and mineral-bone peptides appear as relevant candidate markers for future studies investigating their predictive performance regarding renal allograft outcomes.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world